Log In

Healthcare & Pharmaceuticals Blog

Recent Posts

  • Blog: ALTIUS BlogsThe ELTIF: amendments in the Belgian AIFM LawPosted on June 17, 2021 by
    On 19 April 2021, a draft law on diverse financial provisions (the “Draft Law”) was published. The Draft Law was adopted by the Parliament at the end of May. Amongst other things, it amends the Belgian AIFM Law to integrate the ELTIF fund status. Together with its parliamentary works, the Draft Law finally provides some clarity on this vehicle’s place in the existing Belgian fund framework.Background The status of the European long-term investment fund (“ELTIF”) was introduced a few years ago by Regulation 2015/760 of 29 April 2015 on European long-term investment funds (the “ELTIF Regulation...
    READ FULL ARTICLE
  • Blog: Waller Law BlogOSHAs new mandatory COVID-19 guidance for healthcare employers and employeesPosted on June 10, 2021 by
    The new Emergency Temporary Standard that healthcare employers must implement and adhere to in light of COVID-19 is mandatory.
    READ FULL ARTICLE
  • Blog: Homeostasis: Dykema Health Care Law BlogNew COVID-19 Vaccine Requirements for Nursing HomesPosted on May 20, 2021 by David R. Padalino, Kathleen A. Reed
    On May 13, 2021, the Centers for Medicare and Medicaid Services (“CMS”) published an interim final rule with comment period addressing COVID vaccine education, administration, and reporting requirements for nursing homes. Designed to reduce the spread of COVID-19, the rule updates the existing infection control requirements that nursing homes must meet to participate in the Medicare program, found at 42 C.F.R § 483.80. The effective date for the new rule is May 21, 2021, and Michigan’s state survey and certification staff have advised that they will begin enforcement of...
    READ FULL ARTICLE
  • Blog: Patent 213Stanford’s Method for Inferring Haplotype Phase is Not Patent EligiblePosted on April 6, 2021 by Andrew Tuggle and Jessica L. Zurlo
    Stanford University applied for a U.S. patent for statistical methods of predicting haplotype phase. In 2019, the Patent Trial and Appeal Board rejected the application as ineligible subject matter. Last week, a panel of the U.S. Court of Appeals for the Federal Circuit affirmed. The opinion is interesting for being related to two, often separate...
    READ FULL ARTICLE
  • Blog: Biologics BlogFederal Circuit Upholds Jury Award, Weighs in on Willfulness Standard, in Adynovate® DisputePosted on March 29, 2021 by
    According to the Federal Circuit, $173 million was the right damages award for almost three years of patent infringement resulting from Baxalta’s sale of its biologic product Adynovate® (Antihemophilic Factor (Recombinant), PEGylated).  In Bayer Healthcare LLC v. Baxalta Inc., et al., Nos. 2019-2418, 2020-1017 (Fed. Cir. 2021), the circuit court upheld an award to Bayer [...]
    READ FULL ARTICLE
  • Blog: Chemical Law & Prop 65 BlogMajor Changes Coming to Prop 65 “Short-Form” WarningsPosted on February 1, 2021 by
    By: Anne Marie Ellis, John Epperson, Peter McGaw
    READ FULL ARTICLE

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020